TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04660669

Intervention type: OTHER
Group type: OTHER
Intervention: ESDM intervention
Description: Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: ESDM intervention
Description: Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: MOOC
Description: Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
Study: NCT05866172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAIC
Description: hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4mg iv.drip
Study: NCT06212206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillBot
Description: The PillBot System uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator.
Study: NCT05218304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
Study: NCT06112067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
Study: NCT00737542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NACL 0.9%
Study: NCT04463225

Intervention type: OTHER
Group type: OTHER
Intervention: Internet-Delivered Brief Intervention
Description: The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
Study: NCT04991909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800
Description: HRS4800
Study: NCT05228080

Intervention type: DIAGNOSTIC_TEST
Intervention: enzyme-linked immunosorbent assay(ELISA)
Description: Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
Study: NCT05495191

Intervention type: DIAGNOSTIC_TEST
Intervention: Signal intensity gradient
Description: In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)

Intervention type: DIAGNOSTIC_TEST
Intervention: Signal intensity gradient
Description: In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)
Study: NCT06026098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Participants will use the Artificial Intelligence assistance tool for case reports.
Study: NCT06640491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO Administration of Cefazolin
Description: Intraosseous injection of cefazolin to guard against infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO Administration of Vancomycin
Description: Intraosseous injection of vancomycin to guard against infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Administration of Cefazolin
Description: Intravenous dose of cefazolin to guard against infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Administration of Vancomycin
Description: Intravenous dose of vancomycin to guard against infection.
Study: NCT04991909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06278701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: late-evening snacks
Description: have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
Study: NCT05456997

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
Study: NCT05817955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) with Ruxolitinib
Description: 1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture.
Study: NCT05456997

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
Study: NCT05144893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Mindfullness-Based Intervention
Description: Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
Study: NCT06643858

Intervention type: OTHER
Intervention: No intervention
Description: This study does not involve any interventions.

Intervention type: OTHER
Intervention: No intervention
Description: This study does not involve any interventions.
Study: NCT06110364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Tragus Stimulation
Description: Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability- Biofeedback
Description: Heart Rate Variability- Biofeedback will be monitored with a Holter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Therapy
Description: Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
Study: NCT05783128

Intervention type: OTHER
Intervention: Airway management techniques (exposure)
Description: The exposure reffers to the different methods of airway management during general or regional anesthesia.

Intervention type: OTHER
Intervention: Airway management techniques (exposure)
Description: The exposure reffers to the different methods of airway management during general or regional anesthesia.

Intervention type: OTHER
Intervention: Airway management techniques (exposure)
Description: The exposure reffers to the different methods of airway management during general or regional anesthesia.
Study: NCT05438394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan hydrochloride for injection
Description: Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
Study: NCT05598541

Intervention type: PROCEDURE
Intervention: Surgical or non-surgical treatment
Description: Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)

Intervention type: PROCEDURE
Intervention: Surgical or non-surgical treatment
Description: Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
Study: NCT05509920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-PRG barrier coat
Description: S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-PRG barrier coat
Description: S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
Study: NCT05783128

Intervention type: OTHER
Intervention: Airway management techniques (exposure)
Description: The exposure reffers to the different methods of airway management during general or regional anesthesia.
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06435988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the pecha kucha technique
Description: Providing labor training to pregnant women with the Pecha Kucha technique
Study: NCT04910529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
Study: NCT05439278

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 40.05 Gy in 15 fractions (daily treatment, 5 per week)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy
Description: 60 Gy in 30 fractions (daily treatment, 5 per week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
Study: NCT04648488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental early mobilisation
Description: early activ assisted exercises treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aktive comparator standrad treatmnet
Description: standard treatment with a plaster 3 weeks and then active assisted exercises
Study: NCT05561816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxymethylquinoxalindioxyde
Description: Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Description: Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
Study: NCT04262882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel Family Planning Intervention
Description: The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time and attention matched control
Description: This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda.
Study: NCT05135559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.
Study: NCT05964348

Intervention type: PROCEDURE
Intervention: CT-Scan
Description: semi-automated analyse by anatomical landmarks with a dedicated fully automated software
Study: NCT06107751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position group
Description: This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sniffing position group
Description: This position will be achieved by placing a 7 cm pillow under the occiput.
Study: NCT05507125

Intervention type: BEHAVIORAL
Intervention: Mental health
Description: Early life exposure to abuse and development of hidradenitis suppurativa

Intervention type: BEHAVIORAL
Intervention: Mental health
Description: Early life exposure to abuse and development of hidradenitis suppurativa
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06413563

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05363722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310（0.5mg/kg）
Description: IBI310 0.5mg/kg IV d1 Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310（0.3mg/kg）
Description: IBI310 0.3mg/kg IV d1 Q6W
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05363722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: sintilimab 200 mg IV d1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: sintilimab 200 mg IV d1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg IV d1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg IV d1，Q3W
Study: NCT04974840

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training combined with/ without thera-band
Description: Treadmill walking training with thera-band Treadmill walking training without thera-band

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training combined with/ without thera-band
Description: Treadmill walking training with thera-band Treadmill walking training without thera-band
Study: NCT04700761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia
Description: Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-using anesthesia
Description: Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
Study: NCT05744778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy and rehabilitation
Description: The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy and rehabilitation
Description: The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.